These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 14740605)

  • 21. Unfair competition under the TRIPS agreement: protection of data submitted for the registration of pharmaceuticals.
    Correa CM
    Chic J Int Law; 2002; 3(1):69-85. PubMed ID: 15709300
    [No Abstract]   [Full Text] [Related]  

  • 22. Academic patents and access to medicines in developing countries.
    Sampat BN
    Am J Public Health; 2009 Jan; 99(1):9-17. PubMed ID: 19008514
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Patents and availability of essential drugs].
    Carné X
    Med Clin (Barc); 2007 Nov; 129(16):617-8. PubMed ID: 18001674
    [No Abstract]   [Full Text] [Related]  

  • 24. WTO TRIPS and its effect on the supply and development of medicines in China.
    Tanner JA
    Hong Kong Med J; 2006 Feb; 12(1):84-6. PubMed ID: 16495599
    [No Abstract]   [Full Text] [Related]  

  • 25. Trans-Pacific Partnership Provisions in Intellectual Property, Transparency, and Investment Chapters Threaten Access to Medicines in the US and Elsewhere.
    Baker BK
    PLoS Med; 2016 Mar; 13(3):e1001970. PubMed ID: 26954325
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pills, patents, and power: state creation of gray markets as a limit on patent rights.
    Ghosh S
    Fla J Int Law; 2002; 14(2):217-60. PubMed ID: 16526138
    [No Abstract]   [Full Text] [Related]  

  • 27. Why are generic drugs being held up in transit? Intellectual property rights, international trade, and the right to health in Brazil and beyond.
    Rosina MS; Shaver L
    J Law Med Ethics; 2012; 40(2):197-205. PubMed ID: 22789040
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmaceutical companies and global lack of access to medicines: strengthening accountability under the right to health.
    Grover A; Citro B; Mankad M; Lander F
    J Law Med Ethics; 2012; 40(2):234-50. PubMed ID: 22789043
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmaceutical patents and some international trade issues: Canada, the United States, and NAFTA.
    Tancer RS
    Clin Ther; 1993; 15(6):1177-84; discussion 1120. PubMed ID: 8111813
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tripping over patents: AIDS, access to treatment and the manufacturing of scarcity.
    Berger JM
    Conn J Int Law; 2002; 17(2):157-248. PubMed ID: 12688292
    [No Abstract]   [Full Text] [Related]  

  • 31. Intellectual property rights, the World Trade Organization and public health: the Brazilian perspective.
    Viana JM
    Conn J Int Law; 2002; 17(2):311-8. PubMed ID: 12688298
    [No Abstract]   [Full Text] [Related]  

  • 32. Access to essential medicines: a Hobbesian social contract approach.
    Ashcroft RE
    Dev World Bioeth; 2005 May; 5(2):121-41. PubMed ID: 15842722
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patent necessity: intellectual property dilemmas in the biotech domain and treatment equity for developing countries.
    Spectar JM
    Houst J Int Law; 2002; 24(2):227-78. PubMed ID: 16189914
    [No Abstract]   [Full Text] [Related]  

  • 34. Cautionary Notes on a Global Tiered Pricing Framework for Medicines.
    Williams OD; Ooms G; Hill PS
    Am J Public Health; 2015 Jul; 105(7):1290-3. PubMed ID: 25973806
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The ethics of intellectual property rights in an era of globalization.
    Shah AK; Warsh J; Kesselheim AS
    J Law Med Ethics; 2013; 41(4):841-51, Table of Contents. PubMed ID: 24446942
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Promotion of access to essential medicines for non-communicable diseases: practical implications of the UN political declaration.
    Hogerzeil HV; Liberman J; Wirtz VJ; Kishore SP; Selvaraj S; Kiddell-Monroe R; Mwangi-Powell FN; von Schoen-Angerer T;
    Lancet; 2013 Feb; 381(9867):680-9. PubMed ID: 23410612
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analyzing the impact of trade and investment agreements on pharmaceutical policy: provisions, pathways and potential impacts.
    Gleeson D; Lexchin J; Labonté R; Townsend B; Gagnon MA; Kohler J; Forman L; Shadlen KC
    Global Health; 2019 Nov; 15(Suppl 1):78. PubMed ID: 31775767
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmaceutical patents and their impact on access to medicines: a focus on the sub-Saharan Africa market.
    Okeniyi SO; Okereke M
    Pharm Pat Anal; 2022 Sep; 11(5):131-133. PubMed ID: 36177777
    [No Abstract]   [Full Text] [Related]  

  • 39. Patent law--balancing profit maximization and public access to technology.
    Beckerman-Rodau A
    Columbia Sci Technol Law Rev; 2003; 4():E1. PubMed ID: 15977333
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impacts of intellectual property provisions in trade treaties on access to medicine in low and middle income countries: a systematic review.
    Islam MD; Kaplan WA; Trachtenberg D; Thrasher R; Gallagher KP; Wirtz VJ
    Global Health; 2019 Dec; 15(1):88. PubMed ID: 31888688
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.